^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Nplate (romiplostim)

    i
    Other names: AMG531, AMG 531, AMG-531
    Associations

    News

    Trials
    Company:
    Amgen, Kyowa Kirin
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    Associations

    News

    Trials
    14d
    Romiplostim for Oral TPO-RA Resistant ITP (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    Nplate (romiplostim)
    23d
    ITJ(QN)2510: A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related Thrombocytopenia (clinicaltrials.gov)
    P1, N=280, Not yet recruiting, Shanghai 10th People's Hospital
    New P1 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    28d
    N01-A-PICIT-GT: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    28d
    N01-A-PICIT-GI: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    1m
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2030 --> Mar 2027 | Initiation date: Jun 2026 --> Nov 2026 | Trial primary completion date: Dec 2028 --> Mar 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    1m
    Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients (clinicaltrials.gov)
    P2, N=50, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Initiation date: Jul 2025 --> Dec 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    1m
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Sep 2030 | Trial primary completion date: Jun 2028 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    2ms
    Romiplostim in the Treatment of Severe Aplastic Anemia (ChiCTR2600121288)
    P2, N=32, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    Nplate (romiplostim)
    2ms
    An Open-Label Preliminary Study of Romiplostim Versus Recombinant Human Thrombopoietin (rhTPO) in Promoting Platelet Engraftment After Haploidentical Transplantation (ChiCTR2600121211)
    P4, N=130, Xiangya Third Hospital of Central South University; Xiangya Third Hospital of Central South University
    New P4 trial
    |
    Nplate (romiplostim)
    2ms
    A Prospective Study Evaluating the Efficacy and Safety of Romiplostim in Platelet Recovery Following Allogeneic Hematopoietic Stem Cell Transplantation (ChiCTR2600120742)
    P=N/A, N=100, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New trial
    |
    Nplate (romiplostim)
    2ms
    A Single-center, Prospective, Single-arm Observational Study of Romiplostim N01 Combined with Standard Immunosuppressive Therapy in Patients with Aplastic Anemia (AA) (ChiCTR2600120617)
    P4, N=30, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    2ms
    Efficacy of Romiplostim and Avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in breast cancer: a multicenter, randomized controlled clinical trial (ChiCTR2600119903)
    P=N/A, N=180, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New trial
    |
    Nplate (romiplostim)